This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Protein Engineering Market Worth $168 Billion By 2017

DALLAS, March 20, 2013 /PRNewswire/ --

The report " Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017", analyses the global protein engineering market by products, technology, applications, and geography with five-year revenue forecasts. It also identifies the factors driving and restraining the global protein engineering market with analysis of trends, opportunities, and threats.

  • 11 market data tables
  • 44 figures
  • 148 Slides and an in-depth Table of Content on " Protein Engineering Market"

Early buyers will receive 10% customization on this report.

The protein engineering market is divided into three segments based on its applications, namely, therapeutics, diagnostics, and research. The protein engineering market includes therapeutic proteins (monoclonal antibodies, insulin analogs, EPO, and other proteins), diagnostic proteins, and engineered proteins used in research applications. Monoclonal antibodies is the fastest growing segment of the protein engineering market; it is further segmented based on its application for cancer, auto immune diseases, inflammatory diseases, neovascular and haemostasis.

The global market for engineered protein products is estimated to be worth $168 billion by 2017, growing at a CAGR of 10.94% from 2012 to 2017. Proteins are used as therapeutics owing to their specificity and less immunogenic responses within the host system. Diversity in protein architecture and its properties offers scope for new and improved versions of therapeutic proteins with improved function and stability. The protein engineering market products is growing due to an increase in prevalence of cancer, autoimmune, inflammatory and infectious diseases. These diseases need a targeted therapeutic approach for treatment, which is achieved by therapeutic proteins. Monoclonal antibody is the fastest growing product segment in the market with more than 50% market share. There are more than 25 monoclonal antibodies approved for therapeutics; 10 of these are blockbuster drugs with more than $1 billion in annual revenue. Other products like insulin analogs, EPO, enzymes, and growth hormones are expected to grow at a medium pace.

U.S. and Europe have been major protein engineering market products; however, Asia is set to grow at a faster pace with India's growth in the field of biotechnology and Chinas interest in the research of monoclonal antibodies. Indonesia is the fourth-largest diabetic population nation, and South Koreas growing cancer incidence rate is expected to propel the market for protein therapeutics in the region.

Key players in the market include Genetech (U.S.), Amgen(U.S.), Roche ( Switzerland), Eli Lilly (U.S.), Novartis ( Switzerland), GSK (U.K.), BMS (U.S.), Johnson & Johnson(U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi ( France), Affymax (U.S.), Biogen Idec (U.S.), and Medimmune (U.S.).

Buy a copy of this report @

  About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs